Geneos Wealth Management Inc. Sells 3,253 Shares of Insulet Corporation $PODD

Geneos Wealth Management Inc. lowered its stake in shares of Insulet Corporation (NASDAQ:PODD) by 9.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,265 shares of the medical instruments supplier’s stock after selling 3,253 shares during the period. Geneos Wealth Management Inc.’s holdings in Insulet were worth $10,137,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Kozak & Associates Inc. bought a new position in Insulet during the second quarter valued at $32,000. Golden State Wealth Management LLC lifted its position in shares of Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 69 shares during the last quarter. Trust Co. of Toledo NA OH bought a new position in shares of Insulet during the 2nd quarter worth $35,000. Osterweis Capital Management Inc. purchased a new stake in Insulet in the 2nd quarter worth about $51,000. Finally, NewEdge Advisors LLC raised its stake in Insulet by 44.8% in the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 64 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Leerink Partners upped their price objective on shares of Insulet from $385.00 to $386.00 and gave the company an “outperform” rating in a report on Friday, November 21st. JPMorgan Chase & Co. upped their price target on shares of Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Stifel Nicolaus initiated coverage on shares of Insulet in a report on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price objective for the company. Sanford C. Bernstein reiterated an “outperform” rating on shares of Insulet in a research note on Friday, November 21st. Finally, Cowen restated a “buy” rating on shares of Insulet in a research report on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $379.65.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $295.70 on Friday. The company has a 50 day moving average of $318.88 and a 200 day moving average of $314.88. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68. The stock has a market cap of $20.80 billion, a P/E ratio of 85.71, a P/E/G ratio of 2.08 and a beta of 1.37. Insulet Corporation has a 12 month low of $230.05 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. The business had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The business’s revenue for the quarter was up 29.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.08 EPS. As a group, sell-side analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.